Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response

References

• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi:10.1126/science.aaa4967
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med. 2012;4(127):127ps8–ps8. doi:10.1126/scitranslmed.3003634
   PubMed Web of Science ®Google Scholar
• Wang HY, Peng G, Guo Z, Shevach EM, Wang R-F. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol. 2005;174(5):2661–2670. doi:10.4049/jimmunol.174.5.2661
   PubMed Web of Science ®Google Scholar
• Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724–740. doi:10.1016/j.cell.2017.01.016
   PubMed Web of Science ®Google Scholar
• Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167(3):829–42. e13. doi:10.1016/j.cell.2016.09.031
   PubMed Web of Science ®Google Scholar
• Herbel C, Patsoukis N, Bardhan K, Seth P, Weaver JD, Boussiotis VA. Clinical significance of T cell metabolic reprogramming in cancer. Clin Transl Med. 2016;5(1):1–23. doi:10.1186/s40169-016-0110-9
   PubMedGoogle Scholar
• Courtney AH, Lo W-L, Weiss A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem Sci. 2018;43(2):108–123. doi:10.1016/j.tibs.2017.11.008
   PubMed Web of Science ®Google Scholar
• Buck MD, O’sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med. 2015;212(9):1345–1360. doi:10.1084/jem.20151159
   PubMed Web of Science ®Google Scholar
• MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013;31(1):259–283. doi:10.1146/annurev-immunol-032712-095956
   PubMed Web of Science ®Google Scholar
• O’Connell P, Hyslop S, Blake MK, Godbehere S, Amalfitano A, Aldhamen YA. SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment. J Immunol. 2021;206(1):193–205. doi:10.4049/jimmunol.2000300
   PubMed Web of Science ®Google Scholar
• Zhang L, Romero P. Metabolic control of CD8+ T cell fate decisions and antitumor immunity. Trends Mol Med. 2018;24(1):30–48. doi:10.1016/j.molmed.2017.11.005
   PubMed Web of Science ®Google Scholar
• O’Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol. 2015;36(2):71–80. doi:10.1016/j.it.2014.12.004
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–799. doi:10.1038/nm1087
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–619. doi:10.1038/nrg1879
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–3899. doi:10.1158/0008-5472.CAN-03-2904
   PubMed Web of Science ®Google Scholar
• Fan Y, Dickman KG, Zong W-X. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem. 2010;285(10):7324–7333. doi:10.1074/jbc.M109.035584
   PubMed Web of Science ®Google Scholar
• Robey RB, Hay N. Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol. 2009;19(1):25–31. doi:10.1016/j.semcancer.2008.11.010
   PubMed Web of Science ®Google Scholar
• Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol. 2005;6(1):44–55. doi:10.1038/nrm1546
   PubMed Web of Science ®Google Scholar
• Matoba S, Kang J-G, Patino WD, et al. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650–1653. doi:10.1126/science.1126863
   PubMed Web of Science ®Google Scholar
• Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–120. doi:10.1016/j.cell.2006.05.036
   PubMed Web of Science ®Google Scholar
• Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8(2):317–325. doi:10.1016/S1097-2765(01)00323-9
   PubMed Web of Science ®Google Scholar
• Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275(29):21797–21800. doi:10.1074/jbc.C000023200
   PubMed Web of Science ®Google Scholar
• Le A, Lane AN, Hamaker M, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1):110–121. doi:10.1016/j.cmet.2011.12.009
   PubMed Web of Science ®Google Scholar
• Young CD, Lewis AS, Rudolph MC, et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011;6(8):e23205. doi:10.1371/journal.pone.0023205
   PubMed Web of Science ®Google Scholar
• Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007;5(4):237–252. doi:10.1016/j.cmet.2007.03.006
   PubMed Web of Science ®Google Scholar
• Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle. 2010;9(19):3884–3886. doi:10.4161/cc.9.19.13302
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11–20. doi:10.1016/j.cmet.2007.10.002
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18(1):54–61. doi:10.1016/j.gde.2008.02.003
   PubMed Web of Science ®Google Scholar
• Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med. 2012;53(3):421–436. doi:10.1016/j.freeradbiomed.2012.05.006
   PubMed Web of Science ®Google Scholar
• Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol. 2009;91(2):233–236. doi:10.1007/s11060-008-9706-2
   PubMed Web of Science ®Google Scholar
• Baysal BE. A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One. 2007;2(5):e436. doi:10.1371/journal.pone.0000436
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362(4):369–370. doi:10.1056/NEJMc0910063
   PubMed Web of Science ®Google Scholar
• Van Vranken JG, Na U, Winge DR, Rutter J. Protein-mediated assembly of succinate dehydrogenase and its cofactors. Crit Rev Biochem Mol Biol. 2015;50(2):168–180. doi:10.3109/10409238.2014.990556
   PubMed Web of Science ®Google Scholar
• Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol. 2016;28(5):514–524. doi:10.1016/j.smim.2016.10.009
   PubMed Web of Science ®Google Scholar
• Krauss S, Brand MD, Buttgereit F. Signaling takes a breath–new quantitative perspectives on bioenergetics and signal transduction. Immunity. 2001;15(4):497–502. doi:10.1016/S1074-7613(01)00205-9
   PubMed Web of Science ®Google Scholar
• Rathmell JC, Vander Heiden MG, Harris MH, Frauwirth KA, Thompson CB. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell. 2000;6(3):683–692. doi:10.1016/S1097-2765(00)00066-6
   PubMed Web of Science ®Google Scholar
• Newsholme E, Crabtree B, Ardawi M. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep. 1985;5(5):393–400. doi:10.1007/BF01116556
   PubMed Web of Science ®Google Scholar
• Newsholme EA, Crabtree B, Ardawi MSM. Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Q J Exp Physiol. 1985;70(4):473–489. doi:10.1113/expphysiol.1985.sp002935
   PubMed Web of Science ®Google Scholar
• Wang R, Dillon CP, Shi LZ, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6):871–882. doi:10.1016/j.immuni.2011.09.021
   PubMed Web of Science ®Google Scholar
• Carr EL, Kelman A, Wu GS, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 2010;185(2):1037–1044. doi:10.4049/jimmunol.0903586
   PubMed Web of Science ®Google Scholar
• Gubser PM, Bantug GR, Razik L, et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat Immunol. 2013;14(10):1064–1072. doi:10.1038/ni.2687
   PubMed Web of Science ®Google Scholar
• van der Windt GJ, Everts B, Chang C-H, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 2012;36(1):68–78. doi:10.1016/j.immuni.2011.12.007
   PubMed Web of Science ®Google Scholar
• O’Sullivan D, van der Windt GJ, Huang S-C-C, et al. Memory CD8+ T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity. 2014;41(1):75–88. doi:10.1016/j.immuni.2014.06.005
   PubMed Web of Science ®Google Scholar
• Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460(7251):103–107. doi:10.1038/nature08097
   PubMed Web of Science ®Google Scholar
• Shi LZ, Wang R, Huang G, et al. HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367–1376. doi:10.1084/jem.20110278
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997;22(7):267–272. doi:10.1016/S0968-0004(97)01061-X
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317–330. doi:10.1038/nri1056
   PubMed Web of Science ®Google Scholar
• Saravia J, Raynor JL, Chapman NM, Lim SA, Chi H. Signaling networks in immunometabolism. Cell Res. 2020;30(4):328–342. doi:10.1038/s41422-020-0301-1
   PubMed Web of Science ®Google Scholar
• Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T‐cell differentiation and function. Immunol Rev. 2012;249(1):43–58. doi:10.1111/j.1600-065X.2012.01152.x
   PubMed Web of Science ®Google Scholar
• Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30(1):39–68. doi:10.1146/annurev-immunol-020711-075024
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(20):3589–3594. doi:10.1242/jcs.051011
   PubMed Web of Science ®Google Scholar
• Yang K, Chi H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin Immunol. 2012;24(6):421–428. doi:10.1016/j.smim.2012.12.004
   PubMed Web of Science ®Google Scholar
• Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30(6):832–844.
   PubMed Web of Science ®Google Scholar
• Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011;12(4):295–303. doi:10.1038/ni.2005
   PubMed Web of Science ®Google Scholar
• Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2020;20(1):55–70. doi:10.1038/s41577-019-0203-y
   PubMed Web of Science ®Google Scholar
• Yang K, Shrestha S, Zeng H, et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity. 2013;39(6):1043–1056. doi:10.1016/j.immuni.2013.09.015
   PubMed Web of Science ®Google Scholar
• Gingras A-C, Raught B, Sonenberg N. mTOR signaling to translation. In: TOR; 2004: 169–197.
   Google Scholar
• Kim D-H, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163–175. doi:10.1016/S0092-8674(02)00808-5
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35. doi:10.1038/nrm3025
   PubMed Web of Science ®Google Scholar
• Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity. 2007;27(2):173–178. doi:10.1016/j.immuni.2007.07.008
   PubMed Web of Science ®Google Scholar
• Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186(6):3299–3303. doi:10.4049/jimmunol.1003613
   PubMed Web of Science ®Google Scholar
• Jacobs SR, Herman CE, MacIver NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol. 2008;180(7):4476–4486. doi:10.4049/jimmunol.180.7.4476
   PubMed Web of Science ®Google Scholar
• Cham CM, Gajewski TF. Glucose availability regulates IFN-γ production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005;174(8):4670–4677. doi:10.4049/jimmunol.174.8.4670
   PubMed Web of Science ®Google Scholar
• Doedens AL, Phan AT, Stradner MH, et al. Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen. Nat Immunol. 2013;14(11):1173–1182. doi:10.1038/ni.2714
   PubMed Web of Science ®Google Scholar
• Michalek RD, Gerriets VA, Nichols AG, et al. Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc Nat Acad Sci. 2011;108(45):18348–18353. doi:10.1073/pnas.1108856108
   PubMed Web of Science ®Google Scholar
• Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39(2):171–183. doi:10.1016/j.molcel.2010.06.022
   PubMed Web of Science ®Google Scholar
• Yang K, Neale G, Green DR, He W, Chi H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol. 2011;12(9):888–897. doi:10.1038/ni.2068
   PubMed Web of Science ®Google Scholar
• Chisolm DA, Savic D, Moore AJ, et al. CCCTC-binding factor translates interleukin 2-and α-ketoglutarate-sensitive metabolic changes in T cells into context-dependent gene programs. Immunity. 2017;47(2):251–67. e7. doi:10.1016/j.immuni.2017.07.015
   PubMed Web of Science ®Google Scholar
• Johnson MO, Wolf MM, Madden MZ, et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell. 2018;175(7):1780–95. e19. doi:10.1016/j.cell.2018.10.001
   PubMed Web of Science ®Google Scholar
• Tan H, Yang K, Li Y, et al. Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation. Immunity. 2017;46(3):488–503.
   PubMed Web of Science ®Google Scholar
• Blagih J, Coulombe F, Vincent EE, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. 2015;42(1):41–54. doi:10.1016/j.immuni.2014.12.030
   PubMed Web of Science ®Google Scholar
• MacIver NJ, Blagih J, Saucillo DC, et al. The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J Immunol. 2011;187(8):4187–4198. doi:10.4049/jimmunol.1100367
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Q, Feng L, Liu Z. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement. Nano Today. 2018;21:55–73. doi:10.1016/j.nantod.2018.06.008
   Web of Science ®Google Scholar
• Cuvier C, Jang A, Hill R. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L+ B) secretion. Clin Exp Metastasis. 1997;15(1):19–25. doi:10.1023/A:1018428105463
   PubMed Web of Science ®Google Scholar
• Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett. 2006;242(1):1–10. doi:10.1016/j.canlet.2005.12.005
   PubMed Web of Science ®Google Scholar
• Kondo A, Yamamoto S, Nakaki R, et al. Extracellular acidic pH activates the sterol regulatory element-binding protein 2 to promote tumor progression. Cell Rep. 2017;18(9):2228–2242. doi:10.1016/j.celrep.2017.02.006
   PubMed Web of Science ®Google Scholar
• Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21(5):268–283. doi:10.1038/s41580-020-0227-y
   PubMed Web of Science ®Google Scholar
• Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003;21(3):473–482. doi:10.1200/JCO.2003.11.132
   PubMed Web of Science ®Google Scholar
• Le Bourgeois T, Strauss L, Aksoylar H-I, et al. Targeting T cell metabolism for improvement of cancer immunotherapy. Front Oncol. 2018;8:237. doi:10.3389/fonc.2018.00237
   PubMed Web of Science ®Google Scholar
• Siska PJ, Beckermann KE, Mason FM, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight. 2017;2(12):12. doi:10.1172/jci.insight.93411
   Web of Science ®Google Scholar
• Ben‐Shoshan J, Maysel‐Auslender S, Mor A, Keren G, George J. Hypoxia controls CD4+ CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α. Eur J Immunol. 2008;38(9):2412–2418. doi:10.1002/eji.200838318
   PubMed Web of Science ®Google Scholar
• Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–790. doi:10.1084/jem.20131916
   PubMed Web of Science ®Google Scholar
• Siska PJ, Rathmell JC. T cell metabolic fitness in antitumor immunity. Trends Immunol. 2015;36(4):257–264. doi:10.1016/j.it.2015.02.007
   PubMed Web of Science ®Google Scholar
• Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc Nat Acad Sci. 2008;105(39):15016–15021. doi:10.1073/pnas.0801497105
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862
   PubMed Web of Science ®Google Scholar
• Sharma S, Yang S-C, Zhu L, et al. Tumor cyclooxygenase-2/Prostaglandin E2–dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005;65(12):5211–5220. doi:10.1158/0008-5472.CAN-05-0141
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–581. doi:10.1038/nature13988
   PubMed Web of Science ®Google Scholar
• Bengsch B, Johnson AL, Kurachi M, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion. Immunity. 2016;45(2):358–373. doi:10.1016/j.immuni.2016.07.008
   PubMed Web of Science ®Google Scholar
• Chang C-H, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–1241. doi:10.1016/j.cell.2015.08.016
   PubMed Web of Science ®Google Scholar
• Ho P-C, Bihuniak JD, Macintyre AN, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162(6):1217–1228. doi:10.1016/j.cell.2015.08.012
   PubMed Web of Science ®Google Scholar
• Siska PJ, van der Windt GJ, Kishton RJ, et al. Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J Immunol. 2016;197(6):2532–2540. doi:10.4049/jimmunol.1502464
   PubMed Web of Science ®Google Scholar
• Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769–777. doi:10.1016/S1074-7613(02)00323-0
   PubMed Web of Science ®Google Scholar
• Geltink RIK, O’Sullivan D, Corrado M, et al. Mitochondrial priming by CD28. Cell. 2017;171(2):385–97. e11. doi:10.1016/j.cell.2017.08.018
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition. Science. 2017;355(6332):1428–1433. doi:10.1126/science.aaf1292
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science. 2017;355(6332):1423–1427. doi:10.1126/science.aaf0683
   PubMed Web of Science ®Google Scholar
• Messmer AS, Que Y-A, Schankin C, et al. CAR T-cell therapy and critical care. Wien Klin Wochenschr. 2021:1–8. doi:10.1007/s00508-021-01948-2
   Web of Science ®Google Scholar
• Pilipow K, Darwich A, Losurdo A. T-cell-based breast cancer immunotherapy. Semin Cancer Biol. 2021;72:90–101. doi:10.1016/j.semcancer.2020.05.019
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553–565. doi:10.1038/nri.2016.70
   PubMed Web of Science ®Google Scholar
• Chang C-H, Pearce EL. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat Immunol. 2016;17(4):364–368. doi:10.1038/ni.3415
   PubMed Web of Science ®Google Scholar
• Freen-van Heeren JJ. Using CRISPR to enhance T cell effector function for therapeutic applications. Cytokine: X. 2021;3(1):100049. doi:10.1016/j.cytox.2020.100049
   PubMedGoogle Scholar
• Riese MJ, Moon EK, Johnson BD, Albelda SM. Diacylglycerol kinases (DGKs): novel targets for improving T cell activity in cancer. Front Cell Develop Biol. 2016;4:108. doi:10.3389/fcell.2016.00108
   PubMed Web of Science ®Google Scholar
• Eichmann TO, Lass A. DAG tales: the multiple faces of diacylglycerol—stereochemistry, metabolism, and signaling. Cell Mol Life Sci. 2015;72(20):3931–3952. doi:10.1007/s00018-015-1982-3
   PubMed Web of Science ®Google Scholar
• Jung I-Y, Kim -Y-Y, Yu H-S, Lee M, Kim S, Lee J. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 2018;78(16):4692–4703. doi:10.1158/0008-5472.CAN-18-0030
   PubMed Web of Science ®Google Scholar
• Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380–390. doi:10.1016/j.immuni.2016.01.021
   PubMed Web of Science ®Google Scholar
• Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci. 2014;10(7):654. doi:10.7150/ijbs.9224
   PubMed Web of Science ®Google Scholar
• Gunton JE, Delhanty PJ, Takahashi S-I, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003;88(3):1323–1332. doi:10.1210/jc.2002-021394
   PubMed Web of Science ®Google Scholar
• Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6). doi:10.3978/j.issn.2305-5839.2014.06.01
   PubMedGoogle Scholar
• Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26(1):94–109. doi:10.1016/j.cmet.2017.06.016
   PubMed Web of Science ®Google Scholar
• Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66(1):17–29. doi:10.1146/annurev-med-062613-093128
   PubMed Web of Science ®Google Scholar
• Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Nat Acad Sci. 2015;112(6):1809–1814. doi:10.1073/pnas.1417636112
   PubMed Web of Science ®Google Scholar
• Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460(7251):108–112. doi:10.1038/nature08155
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484. doi:10.1016/j.cell.2006.01.016
   PubMed Web of Science ®Google Scholar
• Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346–350. doi:10.1038/nature10350
   PubMed Web of Science ®Google Scholar
• Jaccard A, Wenes M, Gyülvészi G, Ho P-C, Romero P. 515 Metabolic reprogramming of antitumor CD8+ T cell immunity. BMJ Specialist J. 2020:8:1
   Google Scholar
• Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immunol. 2015;36(2):81–91. doi:10.1016/j.it.2014.12.005
   PubMed Web of Science ®Google Scholar
• Kim D, Wu Y, Li Q, Oh Y-K. Nanoparticle-mediated lipid metabolic reprogramming of T cells in tumor microenvironments for immunometabolic therapy. Nanomicro Lett. 2021;13(1):1–27. doi:10.1007/s40820-020-00555-6
   Web of Science ®Google Scholar
• Leone RD, Zhao L, Englert JM, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366(6468):1013–1021. doi:10.1126/science.aav2588
   PubMed Web of Science ®Google Scholar
• Renner K, Bruss C, Schnell A, et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 2019;29(1):135–50. e9. doi:10.1016/j.celrep.2019.08.068
   PubMed Web of Science ®Google Scholar